Michael Yi
Partner @ Hillhouse Investment
Beijing, China
Michael Yi is a Series B investor at Hillhouse Investment in Beijing focused on Health Care and Biotechnology. Mr. YI leads Hillhouse Capital’s healthcare investment and has made investments into Wuxi AppTec, Ganlee, BeiGene, Innovent and Junshi, in addition to establishing a China JV with Mayo Clinic-Huimei Healthcare. He holds an MBA from the Marshall School of Business at University of Southern California.
- Total investments:
- 24
- Last investment:
- Lead investor:
- 71%
Last updated:
For AI agents: llms.txt
Industries Michael Yi invests in
Stages Michael Yi invests in
Countries Michael Yi invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 7 (29%)
- Biotechnology 7 (29%)
- Health Diagnostics 4 (17%)
- Medical 3 (13%)
- Biopharma 3 (13%)
Stage
- Series B 7 (29%)
- Series A 3 (13%)
- Series C 2 (8%)
- Series D 2 (8%)
- Post-IPO Equity 1 (4%)
Country
- China 8 (33%)
- United States 3 (13%)
- Singapore 1 (4%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Scivita Medical Technology
|
Scivita Medical is a high-tech enterprise engaged in the field of optical diagnosis and treatment, multidimensional images development, high-performance materials research and precision manufacturing with minimally invasive medical treatment. Scivita Medical's product covers both flexible endoscopy and rigid endoscopy, and has uniqueadvantages in the research and commercialization of all cutting-edge technologies in the field of medical endoscopes. It has ultra-high-definition visualization technology (such as 4K UHD visualization), 3D visualization technology, special light visualization technology (such as fluorescence visualization), ultra-fine endoscopic visualization technology, single-use technology, etc. | $61.9M / Series B / Aug 05, 2021 | |
|
Scivita Medical Technology
|
Scivita Medical is a high-tech enterprise engaged in the field of optical diagnosis and treatment, multidimensional images development, high-performance materials research and precision manufacturing with minimally invasive medical treatment. Scivita Medical's product covers both flexible endoscopy and rigid endoscopy, and has uniqueadvantages in the research and commercialization of all cutting-edge technologies in the field of medical endoscopes. It has ultra-high-definition visualization technology (such as 4K UHD visualization), 3D visualization technology, special light visualization technology (such as fluorescence visualization), ultra-fine endoscopic visualization technology, single-use technology, etc. | $61.9M / Series B / Aug 05, 2021 | |
Pulse
|
Pulse is a health care service provider that assess coronary physiology and biomechanics through innovative techniques. | $100M / Series C / Aug 02, 2021 | |
|
Scivita Medical Technology
|
Scivita Medical is a high-tech enterprise engaged in the field of optical diagnosis and treatment, multidimensional images development, high-performance materials research and precision manufacturing with minimally invasive medical treatment. Scivita Medical's product covers both flexible endoscopy and rigid endoscopy, and has uniqueadvantages in the research and commercialization of all cutting-edge technologies in the field of medical endoscopes. It has ultra-high-definition visualization technology (such as 4K UHD visualization), 3D visualization technology, special light visualization technology (such as fluorescence visualization), ultra-fine endoscopic visualization technology, single-use technology, etc. | $61.7M / Series A / Apr 26, 2021 | |
|
Scivita Medical Technology
|
Scivita Medical is a high-tech enterprise engaged in the field of optical diagnosis and treatment, multidimensional images development, high-performance materials research and precision manufacturing with minimally invasive medical treatment. Scivita Medical's product covers both flexible endoscopy and rigid endoscopy, and has uniqueadvantages in the research and commercialization of all cutting-edge technologies in the field of medical endoscopes. It has ultra-high-definition visualization technology (such as 4K UHD visualization), 3D visualization technology, special light visualization technology (such as fluorescence visualization), ultra-fine endoscopic visualization technology, single-use technology, etc. | $61.7M / Series A / Apr 26, 2021 | |
Cryofocus Biotech
|
Cryofocus Biotech is a Shanghai-based cryoablation device manufacturer, focusing on the application of cryogenic technology in the field of cardiovascular interventional therapy. | Series B / Feb 22, 2021 | |
|
Xingxing Charging
|
Xingxing Charging provides safe and intelligent charging services. | Series B / Jan 01, 2021 | |
Yingsheng Biology
|
Yingsheng Biotechnology Co., Ltd. (referred to as Yingsheng Bio) was established in 2009, and is committed to the application of molecular diagnostic techniques such as maternal and child health, neonatal genetic diseases, metabolic diseases, birth defects and other human genetics, and national eugenics engineering. Yingsheng's product lineincludes 45 innovative genetic metabolic disease screening reagents, 14 vitamins determination reagents, mass spectrometer automatic intelligent processing platform, and ultra-high performance liquid chromatography tandem mass spectrometry detection system. level. | Series B / Nov 12, 2020 | |
HEMO BIOENGINEERING
|
HEMO BIOENGINEERING develops and provides innovative interventional medical devices to patients. | Series B / Oct 19, 2020 | |
InventisBio
|
InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company isco-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas. | $147M / Series D / Sep 27, 2020 | |
| See all 24 investments → | |||
Co-Investors
About Hillhouse Investment
Founded in 2005, Hillhouse is a leading global investment management firm, active across public equity, private equity, real estate and private credit. The firm invests over a long-term horizon and partners with exceptional entrepreneurs to deliver sustainable value creation for quality companies.Hillhouse is a full life-cycle private equityfirm, investing for the long term across opportunities in the healthcare, business services, consumer, and industrials sectors. The firm manages capital on behalf of global institutions such as non-profit foundations, endowments, and pensions.
Hillhouse Investment Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
David Rhee
Partner
|
|||
|
Michael Yi
Partner
|
|||
Zhang Lei
Chairman, Founder, CEO
|
|||
Zhang Lei
Chairman, Founder, CEO
|
|||
Ed Zhang
Venture Partner, HH Bioventure
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Michael Yi invest in?
Michael Yi invests primarily in Health Care, Biotechnology and Health Diagnostics startups, most often at Series B and Series A stage. Most of the 24 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Michael Yi?
Public channels for Michael Yi include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Michael Yi last invest?
The most recent investment recorded for Michael Yi closed in Aug 2021. Shizune tracks 24 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
